STX-241 for advanced EGFR-mutant lung cancer after TKI failure
Part of Cancer, Lungs & breathing clinical trials.
This trial tests an experimental drug called STX-241 for people with a specific type of advanced lung cancer (NSCLC) that has an EGFR mutation (exon 19 deletion or L858R) and has stopped responding to a third-generation EGFR inhibitor (like osimertinib). The drug aims to target a new mutation, C797X, that sometimes appears after osimertinib stops working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of lung cancer called non-small cell lung cancer (NSCLC) that has spread or cannot be removed with surgery.
- Your cancer has a specific change in the EGFR gene (exon 19 deletion or L858R mutation).
- You have already taken a third-generation EGFR inhibitor (like osimertinib) and your cancer got worse while on it.
- After that treatment, tests showed your cancer has a new mutation called C797X (and, for some parts, no T790M mutation).
- You are in fairly good health, able to care for yourself, and your major organs (heart, kidneys, liver, blood) are working well enough.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, STX-721, for people with advanced non-small cell lung cancer that has a specific genetic change (EGFR or HER2 exon 20 insertion). The study aims to see if the drug is safe and effective.
This trial tests a new drug called STX-001, which is injected directly into a tumor to help the immune system fight cancer. It is being studied alone or with another immunotherapy (pembrolizumab) for people with advanced solid tumors, including melanoma or triple-negative breast cancer.
This trial tests a new drug, XTX501, for people with advanced non-small cell lung cancer or other solid tumors. It aims to see if the drug can help shrink tumors or slow their growth.
This Phase 1 study tests whether combining MRX-2843 with osimertinib can help control advanced lung cancer that has specific EGFR gene changes. It is designed to find the safest dose and check early signs of tumor response.
This trial tests a new approach for patients with advanced non-small cell lung cancer that has a specific EGFR mutation (Ex19del or L858R) and has started to grow again after at least six months on osimertinib. It combines two types of focused radiation with continued osimertinib to treat only the progressing spots while keeping the rest of the disease under control.
This trial tests a new drug, HSK40118, for people with advanced non-small cell lung cancer (NSCLC) that has an EGFR mutation and has been treated with certain EGFR-targeted therapies before. The goal is to see if this drug can help when other treatments stop working.
Hear when a new Non-small Cell Lung Cancer (NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.